Photo of Eric Alexander

A mere two weeks ago, we praised a California federal court for dismissing preempted claims against a prescription drug manufacturer and not giving the plaintiff a third chance to plead a non-preempted claim.  We noted that allowing three strikes seems to be the default rule on serial amendments in response to motions to dismiss or…

Over the life of the Blog, there have been many posts taking issue with the pro-plaintiff leanings of California courts, which have resulted in many questionable decisions on issues ranging from expanding personal jurisdiction to shrinking preemption to re-writing the duties of medical product manufacturers under California law.  We have also thrown more than a…

Long ago, it seemed that large-scale drug or device litigation was usually spurred on by a recall, market withdrawal, or major labeling change describing a new risk or limiting the scope of product use.  The plaintiff lawyers these days seem to be more willing to put their energy into attacking currently marketed products without triggering…

As we have said before, the Blog is unabashedly pro-science.  There is a difference between good science and bad science, and reliance on the latter to make any important decision—be it in everyday life, litigation, or public policy—is not smart.  We are also unabashedly in favor of strict application of the Rules of Evidence…

This post comes from the non-RS and non-Dechert side of the Blog.

The great post-modern existentialist philosopher John Madden once said, “If you have two quarterbacks, you actually have no quarterback.”  This was not the result of a fanciful math equation where you (impermissibly) divide by zero.  In American football, except on rare trick plays…

The now well-known requirement from the TwIqbal cases that a complaint contains factual allegations that establish that relief is plausible derives from Rule 8(a)(2) requirement that each pleading contain “a short and plain statement of the claim showing that the pleader is entitled to relief.”  One recurring point of contention in drug and device litigation…

This post is from the non-RS side of the Blog.

Consider the following scenario.  A fifty-two-year-old woman has end-stage left ventricular heart failure despite medical care and the latest medications.  Her prospects for a heart transplant or the implantation of a left-ventricular assist device to prolong her life are limited, including by financial considerations.  She…